These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 29571084)

  • 1. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.
    Gatalica Z; Xiu J; Swensen J; Vranic S
    Eur J Cancer; 2018 May; 94():179-186. PubMed ID: 29571084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.
    Goodman AM; Piccioni D; Kato S; Boichard A; Wang HY; Frampton G; Lippman SM; Connelly C; Fabrizio D; Miller V; Sicklick JK; Kurzrock R
    JAMA Oncol; 2018 Sep; 4(9):1237-1244. PubMed ID: 29902298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
    Devereaux KA; Charu V; Zhao S; Charville GW; Bangs CD; van de Rijn M; Cherry AM; Natkunam Y
    Hum Pathol; 2018 Dec; 82():39-45. PubMed ID: 30539796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
    Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J
    Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
    Sivapiragasam A; Ashok Kumar P; Sokol ES; Albacker LA; Killian JK; Ramkissoon SH; Huang RSP; Severson EA; Brown CA; Danziger N; McGregor K; Ross JS
    Cancer Med; 2021 Jan; 10(1):53-61. PubMed ID: 33314633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 expression and microsatellite instability (MSI) in cancer of unknown primary site.
    Junior JNA; Preto DD'; Lazarini MEZN; de Lima MA; Bonatelli M; Berardinelli GN; da Silva VD; Pinheiro C; Reis RM; Cárcano FM
    Int J Clin Oncol; 2024 Jun; 29(6):726-734. PubMed ID: 38528294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
    Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
    Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
    Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
    Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and immune profiling for cancer of unknown primary site.
    Haratani K; Hayashi H; Takahama T; Nakamura Y; Tomida S; Yoshida T; Chiba Y; Sawada T; Sakai K; Fujita Y; Togashi Y; Tanizaki J; Kawakami H; Ito A; Nishio K; Nakagawa K
    J Immunother Cancer; 2019 Sep; 7(1):251. PubMed ID: 31519206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas.
    Senarathne W; Vranic S; Xiu J; Rose I; Gates P; Gatalica Z
    Ann Diagn Pathol; 2018 Apr; 33():62-68. PubMed ID: 29566951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
    Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C
    Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.
    Jones NL; Xiu J; Rocconi RP; Herzog TJ; Winer IS
    Gynecol Oncol; 2020 Feb; 156(2):393-399. PubMed ID: 31882243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future.
    Yamashita H; Nakayama K; Ishikawa M; Ishibashi T; Nakamura K; Sawada K; Yoshimura Y; Tatsumi N; Kurose S; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31623180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
    Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
    JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers.
    Salem ME; Puccini A; Grothey A; Raghavan D; Goldberg RM; Xiu J; Korn WM; Weinberg BA; Hwang JJ; Shields AF; Marshall JL; Philip PA; Lenz HJ
    Mol Cancer Res; 2018 May; 16(5):805-812. PubMed ID: 29523759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
    Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
    Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis.
    Zou Y; Hu X; Zheng S; Yang A; Li X; Tang H; Kong Y; Xie X
    EBioMedicine; 2021 Jan; 63():103137. PubMed ID: 33310681
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Li L; Li M; Jiang Z; Wang X
    Cells; 2019 Jul; 8(7):. PubMed ID: 31277418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers.
    Contos G; Baca Y; Xiu J; Brown J; Holloway R; Korn WM; Herzog TJ; Jones N; Winer I
    Gynecol Oncol; 2021 Nov; 163(2):312-319. PubMed ID: 34563366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.